EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma

Akihiko Izumi iD, Takayoshi Tachibana iD, Hiroto Ishii iD, Shin-Ichiro Fujiwara iD, Yuho Najima iD, Chikako Ohwada, Kota Yoshifuji, Yuto Hibino, Masatsugu Tanaka iD, Shinichi Kako iD, Shun-Ichi Kimura iD, Masaharu Tamaki iD und 10 weitere

Hematological Oncology · 2025

DOI: 10.1002/hon.70136 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2025. Verfasst von Akihiko Izumi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, C-Reactive Protein, Lymphoma, Blood Platelets. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies have shown that the pre‐transplant C‐reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021. CP ratio was defined as CRP [mg/dL]/platelet [10 4/ μL] and evaluated prior to alloHCT. The cutoff value for CP ratio was set at 0.05 based on previous studies. A total of 311 cases were analyzed, of which 134 were mature B cell lymphoma, 177 were T/NK cell lymphoma (including 70 cases of adult T‐cell leukemia/lymphoma), and 17 were Hodgkin's lymphoma. The median age was 53 years (range: 17–69 years). High CP ratio was associated with status of disease, presence of infections, poor performance status at alloHCT, and high transfusion volume received prior to alloHCT. Overall survival (OS) at 2 years according to CP ratio (low vs. high) was 61.1% versus 30.1% ( p < 0.001), non‐relapse mortality (NRM) was 21.4% versus 40.7% ( p = 0.001), and the relapse rate was 23.7% versus 32.6% ( p = 0.061), respectively. In multivariate analysis, the high CP ratio group was associated with poor OS (HR = 2.20, 95% CI: 1.61–3.02, p < 0.001) and higher NRM (HR = 1.90, 95% CI: 1.28–2.81, p = 0.0014). High CP ratio was found to be associated with poor post‐transplant OS and NRM, and was a suitable prognostic biomarker for stratifying the risk of patients with ML who are candidates for alloHCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationC-Reactive ProteinLymphomaBlood PlateletsBiomarkers, TumorHumansMiddle AgedMaleAdultFemaleAgedRetrospective StudiesPrognosisAdolescentYoung AdultTransplantation, HomologousPlatelet CountSurvival RateBiomarkersFollow-Up Studies

Stichwörter der Autor:innen

C‐reactive proteinbiomarkerhematopoietic stem cell transplantationlymphomaplatelets

Substanzen

C-Reactive ProteinBiomarkers, TumorBiomarkers

Autor:innen und Institutionen

  • Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
  • Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan.
  • Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.

ORCID-Profile: Akihiko Izumi, Takayoshi Tachibana, Hiroto Ishii, Shin-Ichiro Fujiwara, Yuho Najima, Masatsugu Tanaka, Shinichi Kako, Shun-Ichi Kimura, Masaharu Tamaki, Shokichi Tsukamoto, Noriko Doki, Takuya Miyazaki, Yoshinobu Kanda

Zitieren

APA

Izumi, A., Tachibana, T., Ishii, H., Fujiwara, S. I., Najima, Y., Ohwada, C., Yoshifuji, K., Hibino, Y., Tanaka, M., Kako, S., Kimura, S. I., Tamaki, M., Yano, S., Yokoyama, H., Minakata, D., Tsukamoto, S., Sakaida, E., Doki, N., Yokota, A., …, & Kanda, Y. (2025). Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70136

Vancouver

Izumi A, Tachibana T, Ishii H, Fujiwara SI, Najima Y, Ohwada C, et al. Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70136

BibTeX
@article{Izumi2025,
  author = {Izumi, Akihiko and Tachibana, Takayoshi and Ishii, Hiroto and Fujiwara, Shin-Ichiro and Najima, Yuho and Ohwada, Chikako and Yoshifuji, Kota and Hibino, Yuto and Tanaka, Masatsugu and Kako, Shinichi and Kimura, Shun-Ichi and Tamaki, Masaharu and Yano, Shingo and Yokoyama, Hiroki and Minakata, Daisuke and Tsukamoto, Shokichi and Sakaida, Emiko and Doki, Noriko and Yokota, Akira and Miyazaki, Takuya and Aotsuka, Nobuyuki and Kanda, Yoshinobu},
  title = {Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70136}
}
Kostenlos starten →